Summary
BerGenBio AS (BerGenBio) is a biotechnology company that develops drugs for aggressive and drug resistant cancers. The company develops epithelial-mesenchymal transition (EMT) inhibitors for acquired cancer drug-resistance and metastasis. The company’s lead product candidate BGB324 finds application in the treatment of drug resistant chronic myeloid leukemia. BerGenBio’s cellselect, a drug discovery and validation technology identifies and validate novel drug targets and biomarkers. The company’s cellselect imaging allows cell sorting, selection and in-vivo disease imaging; cellselect modelling and regulated translational tool is used in treating in-vivo modeling. The company works in partnership with international bio-pharma companies. BerGenBio is headquartered in Bergen, Norway.
BerGenBio AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
BerGenBio AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
BerGenBio AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
BerGenBio AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
BerGenBio AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
BerGenBio AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
BerGenBio AS, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
BerGenBio Raises US$6.4 Million In Venture Financing 10
BerGenBio Secures US$8.8 Million In Series A Financing 11
BerGenBio Secures US$1.3 Million In Venture Financing 12
Partnerships 13
BerGenBio Enters into Agreement with Merck 13
Licensing Agreements 14
Rigel Pharma Enters Into Licensing Agreement With BerGenBio For BGB324 14
Equity Offering 15
BerGenBio Raises USD25 Million in Private Placement of Shares 15
BerGenBio Raises USD12 Million in Private Placement of Shares 16
BerGenBio Completes Private Placement Of Common Stock For US$11.9 Million 17
BerGenBio AS - Key Competitors 19
Key Employees 20
Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22
List of Tables
BerGenBio AS, Pharmaceuticals & Healthcare, Key Facts 1
BerGenBio AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
BerGenBio AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
BerGenBio AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
BerGenBio AS, Deals By Therapy Area, 2011 to YTD 2017 8
BerGenBio AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
BerGenBio Raises US$6.4 Million In Venture Financing 10
BerGenBio Secures US$8.8 Million In Series A Financing 11
BerGenBio Secures US$1.3 Million In Venture Financing 12
BerGenBio Enters into Agreement with Merck 13
Rigel Pharma Enters Into Licensing Agreement With BerGenBio For BGB324 14
BerGenBio Raises USD25 Million in Private Placement of Shares 15
BerGenBio Raises USD12 Million in Private Placement of Shares 16
BerGenBio Completes Private Placement Of Common Stock For US$11.9 Million 17
BerGenBio AS, Key Competitors 19
BerGenBio AS, Key Employees 20
List of Figures
BerGenBio AS, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
BerGenBio AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
BerGenBio AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
BerGenBio AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
BerGenBio AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
BerGenBio AS, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
BerGenBio AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
BerGenBio AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8